Does Transplant Genomics pay their employees well?

According to anonymously submitted Glassdoor reviews, Transplant Genomics employees rate their compensation and benefits as 3.0 out of 5. Find out more about salaries and benefits at Transplant Genomics. This rating has decreased by 7% over the last 12 months.

How satisfied are employees working at Transplant Genomics?

25% of Transplant Genomics employees would recommend working there to a friend based on Glassdoor reviews . Employees also rated Transplant Genomics 3.5 out of 5 for work life balance, 3.2 for culture and values and 2.4 for career opportunities.

What are employees saying about Transplant Genomics redundancies in 2026?

Explore Glassdoor’s employee reviews to understand what current and former employees are saying about Transplant Genomics redundancy and their outlook for job security at Transplant Genomics in 2026.

Transplant Genomics Reviews

3.0

25% would recommend to a friend

(25 total reviews)

30% positive business outlook

Transplant Genomics has an employee rating of 3.0 out of 5 stars, based on 25 company reviews on Glassdoor which indicates that most employees have an average working experience there. The Transplant Genomics employee rating is in line with the average (within 1 standard deviation) for employers within the Pharmaceutical and biotechnology industry (3.5 stars).

Reviews by job title

25 reviews

2.0

8 May 2023

A horrible end to an organization that had great potential

Anonymous employee

Recommend

CEO approval

Business outlook

Pros

Overwhelming commitment to the mission. Most everyone sincerely cared about serving vulnerable transplant patients through noninvasive rejection testing.

Cons

Perhaps it was doomed from the start? Launching a test for immunocompromised patients right before the COVID-19 pandemic started was horrible luck. It took a lot longer to gain traction in the marketplace, which made it difficult to ever hit the aggressive growth forecast Eurofins had for TGI. The death knell came with the Medicare reimbursement changes in April 2023 which cut the company revenue by more than half, leading to a massive layoff.

3.0

2 Feb 2026

Amazing Product Lost to Poor Management

Manager

Recommend

CEO approval

Business outlook

Pros

Great Team, Great Product, Solid Science & product. DEI program is fantastic.

Cons

Eurofins' management of Transplant Genomics and the Diagnostic arm of their testing is very poor. Decisions are made with the bottom line in mind and not of the product or longevity. 2 Major RIFs in 3 years. Paying 20% under going rate across the board.

2.0

25 Sept 2023

Wouldn't Recommend

Anonymous employee

Recommend

CEO approval

Business outlook

Pros

The work being done is amazing, it was nice to know that the results I was putting out had an impact on patient's lives in a very direct way.

Cons

The Lenexa lab was micromanaged in a way that made progress impossible. Upper management churned and burned through two new operations managers in less than 6 months, both had great potential but were completely overwhelmed and hamstrung. Leadership is unaware of the pressures they put on those below them and are contradictory, micromanaging, and uncommunicative. There were constant battles between the sister company of Viracor and the Fremont lab (which no longer exists) You're expected to be perfect.

Viewing 1 - 3 of 25 Reviews